Grid laser with modified pro re nata injection of bevacizumab and ranibizumab in macular edema due to branch retinal vein occlusion: MARVEL report no 2

Clinical Ophthalmology

Volumn 10, Issue , 2016, Pages 1023-1029

  Narayanan, Raja ^a   Panchal, Bhavik ^a   Stewart, Michael W ^b   Das, Taraprasad ^a   Chhablani, Jay ^a   Jalali, Subhadra ^a   Ali, Mohd Hasnat ^a  

^a L V PRASAD EYE INSTITUTE   (India)

^b MAYO CLINIC   (United States)

Author keywords

Grid laser; PRN dosing; Randomized clinical trial; Visual acuity

Indexed keywords

BEVACIZUMAB; CREATININE; RANIBIZUMAB;

ADULT; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CATARACT; CENTRAL RETINAL THICKNESS; CHIKUNGUNYA; CONJUNCTIVITIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; EPIRETINAL MEMBRANE; FEMALE; FOOT FRACTURE; GRID LASER PHOTOCOAGULATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFORMED CONSENT; INTRACRANIAL PRESSURE; JAUNDICE; LASER COAGULATION; MACULAR EDEMA; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; SIDE EFFECT; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS HEMORRHAGE;

EID: 84973645508     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S104459     Document Type: Article

References (22)

1. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia: the Blue Mountains Eye Study. Arch Ophthalmol. 1996;114(10):1243-1247.
2. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 2000;98:133-143.
3. Noma H, Mimura T, Yasuda K, Shimura M. Role of soluble vascular endothelial growth factor receptors-1 and -2, their ligands, and other factors in branch retinal vein occlusion with macular edema. Invest Ophthalmol Vis Sci. 2014;55(6):3878-3885.
4. Sohn HJ, Han DH, Kim IT, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol. 2011;152(4):686-694.
5. Garrido-Urbani S, Bradfield PF, Lee BP, Imhof BA. Vascular and epithelial junctions: a barrier for leucocyte migration. Biochem Soc Trans. 2008;36(Pt 2):203-211.
6. Bates DO, Curry FE. Vascular endothelial growth factor increases microvascular permeability via a Ca(2+)-dependent pathway. Am J Physiol. 1997;273(2 Pt 2):H687-H694.
7. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci. 1995;108(Pt 6):2369-2379.
8. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1102-1112.
9. Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011;118(8):1594-1602.
10. Campochiaro PA, Clark WL, Boyer DS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology. 2015;122(3):538-544.
11. Narayanan R, Panchal B, Das T, Chhablani J, Jalali S, Ali MH. A randomized, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1. Br J Ophthalmol. 2015;99(7):954-959.
12. Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Arch Ophthalmol. 1992;110:1427-1434.
13. Jonas JB, Akkoyun I, Kamppeter B, Kreissig I, Degenring RF. Branch retinal vein occlusion treated by triamcinolone acetonide. Eye (Lond). 2005;19(1):65-71.
14. Chen SD, Sundaram V, Lochhead J, Patel CK. Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion. Am J Ophthalmol. 2006;141(5):876-883.
15. SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study report 6. Arch Ophthalmol. 2009;127(9):1115-1128.
16. Haller JA, Bandello F, Belfort R Jr, et al; for the OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6):1134-1146.e3.
17. Comparison of Age-related Macular Degeneration Treatment Trials (CATT) Research Group; Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-1398.
18. Chakravarthy U, Harding SP, Rogers CA, et al; IVAN Study Investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomized controlled trial. Lancet. 2013;382(9900):1258-1267.
19. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480-1487.
20. Kreutzer TC, Alge CS, Wolf AH, et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol. 2008;92(3):351-355.
21. Donati S, Barosi P, Bianchi M, Al Oum M, Azzolini C. Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion. Eur J Ophthalmol. 2012;22(4):607-614.
22. Ehlers JP, Decroos FC, Fekrat S. Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion. Retina. 2011;31(9):1856-1862.